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Background: Fatty acids are essential dietary nutrients, and one of their important roles is providing polyunsaturated
fatty acids (PUFAs) for the growth and function of nervous tissue. Short chain fatty acids (SCFAs) are a group of
compounds derived from the host microbiome that were recently linked to effects on the gut, the brain, and behavior.
They are therefore linked to neurodevelopmental disorders such as autism. Reduced levels of PUFAs are associated
with impairments in cognitive and behavioral performance, which are particularly important during brain development.
Recent studies suggest that omega −3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) are involved in neurogenesis, neurotransmission, and protection from oxidative stress. Omega-3 PUFAs mediate
some of these effects by antagonizing Omega-6 PUFA (arachidonic acid, AA)-induced proinflammatory prostaglandin
E₂ (PGE₂) formation.
Methods: In this work, the absolute and relative concentrations of propionic (PPA), butyric and acetic acids, as well as
PUFAs and their precursors (α-Linolenic and linoleic), were measured in the brain tissue of PPA-neurointoxicated rat
pups (receiving 250 mg PPA/Kg body weight for 3 consecutive days) as a rodent model with persistent autistic features
compared with healthy controls.
Results: The data revealed remarkably lower levels of omega6/omega3, α-Linolenic/Linoleic, α-Linolenic/EPA,
α-Linolenic/DHA, EPA/DHA, and AA/Linoleic acid ratios in PPA-intoxicated rats. The role of these impaired ratios is
discussed in relation to the activity of desaturases and elongases, which are the two enzymatic groups involved in the
synthesis of PUFAs from their precursors. The relationship between the abnormal relative concentrations of the studied
fatty acids and oxidative stress, neurotransmission, and neuroinflammation is also discussed in detail.
Conclusions: This study demonstrates that fatty acid ratios are useful for understanding the mechanism of PPA
neurotoxicity in a rodent model of autism. Therefore, it is possible to use these ratios for predictions in patients with
this disorder.
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Lipids constitute nearly 60 percent of the brain’s struc-
ture. Fatty acids are among the most important mole-
cules that determine the brain’s integrity and ability to
work efficiently. Clinical observational studies have
linked fatty acid level imbalance to impaired brain per-
formance and diseases such as autism, which is a neuro-
developmental disorder [1]. Physical signs consistent
with fatty acid deficiency such as frequent urination, dull
and dry skin and hair, and brittle nails have been linked
to autism [1]. Additionally, essential fatty acids are im-
portant for brain development during both the fetal and
postnatal period. Beyond their important role in building
the brain’s structure, certain fatty acids act as messen-
gers and are involved in the synthesis and function of
neurotransmitters and the molecules of the immune
system.
Neuronal membranes contain phospholipid pools that
are reservoirs for the synthesis of specific lipid messengers
following neuronal stimulation or injury. These messen-
gers in turn participate in signaling cascades that can pro-
mote either neuronal injury or neuroprotection [2,3].
Dietary essential fatty acids (EFAs) mediate brain func-
tion and structure during development and are involved
in many brain-related disorders such as autism. Fatty
acids are commonly classified as saturated, monounsatu-
rated, or polyunsaturated (PUFA), depending on their
chemical structure and chain length, which can vary
from 12 to 26 carbon bonds. The two types of PUFAs
include EFA, linoleic acid (LA: 18:2, n- 6) and α-
linolenic acid (ALA: 18:3, n-3). The brain cannot distin-
guish between longer chain fatty acids that have been
synthesized in the brain and those that have been ob-
tained from diet and have crossed the blood–brain bar-
rier. Clearly, the blood–brain barrier is key to the
bioavailability of brain EFA and PUFAs.
The short chain fatty acids (SCFAs) acetate (C2), pro-
pionate (C3) and butyrate (C4) are the main metabolic
products of anaerobic bacterial fermentation in the in-
testine. In addition to their important role as fuel for
intestinal epithelial cells, SCFAs modulate different pro-
cesses in the gastrointestinal (GI) tract such as electro-
lyte and water absorption. These fatty acids have been
recognized as potential mediators of the effects of the
gut microbiota on intestinal immune function and gut-
brain axis interaction [4]. Recently it was reported that
the three types of SCFAs (acetate, propionate, and butyr-
ate) reduce the production of proinflammatory factors,
including TNF-α, IL-1β, IL-6, and NO. Additionally,
SCFAs enhance the production of the anti-inflammatory
cytokine IL-10 in low concentrations (1–1,200 μmol/L) [5].
In spite of the protective effects of SCFAs, propionic
acid (PPA) neurotoxicity was recently demonstrated via
intraventricular direct infusion into rat brains [6],passage from the gut to the brain in the case of acute
PPA orally administered to rat pups [7] or Chronic ad-
ministration on postnatal days 5–28 [8] and, most re-
cently, subcutaneous injection once a day (500 mg/kg)
in pregnant rats on gestation days G12–16 [9].
This work is an attempt to understand the mechanism
of PPA neurotoxicity by considering the impact of
relatively impaired level SCFAs and PUFAs in PPA-
intoxicated rats compared with a healthy untreated con-
trol group; the results suggest that the ratio is more
important than the quantity of individual fatty acids.
Material and methods
Animals
The experimental assays for this study were performed
on 16 young (approximately 21 days old) male western
albino rats (45 to 60 g). Rats were obtained from the ani-
mal house of the pharmacy college at King Saud Univer-
sity and were randomly assigned to two groups of eight
rats each. The first group of rats was given a neurotoxic
oral dose of PA (250 mg/kg body weight/day for three
days; n = eight) dissolved in 0.2 M phosphate buffered
saline and was termed the oral buffered PA-treated
group. The second group consisted of rats to which only
phosphate buffered saline was administered and was
used as a control group (n = eight). The two groups of rats
were individually housed under controlled temperature
(21 ± 1°C) with ad libitum access to food and water. The
protocol was approved by the Ethics Committee of the
King Saud University, and all experiments were performed
according to the guidelines of the National Animal Care
and Use Committee.
Fatty acid profiling
Lipids were extracted from the brain tissue, and the fatty
acids were methylated using 3 N methanolic HCL in
sealed vials under nitrogen and incubated at 100°C for
45 min. The methyl esters of the free fatty acids were ex-
tracted with hexane, and the fatty acid composition of
the extract was analyzed with a gas chromatograph
(Helwlett- Packard 5890 series II plus, HP analytical Dir-
ect, Wilmington, DE) equipped with a flame ionization
detector and a 30 m × 0.25 mm× 0.25 μm capillary col-
umn (Omega wax 250# 2–4136, Supelco). The helium gas
flow rate was 1.2 ml/min with a split/flow ratio of 50:1.
Oven temperature was held at 205°C. The injector and de-
tector temperatures were 260 and 262°C, respectively.
Two internal standards, C15:0 and C23:0, were added dur-
ing the analysis. The fatty acids were identified by compar-
ing the retention times with authentic standards [10].
Statistical analysis
An SPSS computer program was used. The results are ex-
pressed as the mean ± S.D., and all statistical comparisons
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0.001 being considered significant. Pearson correlations
were also performed. Receiver Operating Characteristics
analysis (ROC) was performed. The area under the curve,
the cutoff values, and the degree of specificity and sensi-
tivity were calculated. ROC curves are constructed by
plotting the false positive rate (i.e. 100-specificity) against
the true positive rate (i.e. sensitivity). These have been
widely accepted as standard tools for evaluating the per-
formance of biomarkers of toxicity. The AUC has been
widely used as a quantitative index of biomarker perform-
ance in a variety of applied fields [11].
Results
Data representing the absolute and relative values of
SCFAs and PUFAs are presented as the mean ± S.D for 6
independent experiments in Tables 1 and 2. Figures 1
and 2 also present the mean values for each parameter
from 6 independent experiments.
It can be easily seen that SCFA, represented by propio-
nic, butyric and acetic acid, was much higher in the
brains of PPA-intoxicated rat pups compared with
healthy controls. However, PUFAs and their precursors
were significantly lower.
Table 1 also demonstrates a significantly lower acetic/
propionic acid ratio of (0.291 ± 0.051) in treated rats
compared with a higher ratio of (0.431 ± 0.069) in con-
trol untreated animals. A non-significant but still lower
butyric/propionic acid ratio was recorded in intoxicated
rats.
The relative values for PUFA, which are presented in
Table 2, were substantially lower in the intoxicated rats
compared with the control rats. Omega 6/ omega3, α-
Linolenic/Linoleic, and AA/linoleic acid ratios were
significantly lower in the PPA-intoxicated rats. The re-
corded values were 0.502 ± 0.026, 0.671 ± 0.066 and
0.644 ± 0.065, respectively, compared with the much
higher values in the control animals of 0.836 ± 0.056,Table 1 Mean ± S.D for the absolute (mmoles/gm brain tissue

















Table 1 describes the Independent Samples T-Test between the control and propio1.466 ± 0.314, and 1.133 ± 0.081. Other ratios such as α-
Linolenic/EPA, α-Linolenic/DHA, EPA/DHA and AA/
EPA were not significantly different between the two
groups.
Tables 3 and 4 demonstrate the ROC analysis of the
absolute and relative ratios of the measured SCFAs and
PUFAs. Satisfactory specificity and sensitivity values
were recorded for most of these fatty acids.
Table 5 demonstrates Pearson correlations between
the neurotoxin PPA and different absolute and relative
concentrations of SCFAs and PUFAs.
Discussion
Understanding lipid and EFA metabolism is crucial for
maintaining both physical and mental health. Working
with the brain tissues of a rodent model orally intoxi-
cated with PPA could offer new insight into brain distur-
bances related to the absolute and relative abundance of
SCFAs and PUFAs and their relationship to different
lipid mediators, such as leukotrienes and prostaglandins.
It is well known that PGE2, which is an anti-inflammatory
prostanoid, is induced by SCFAs. In addition to classical
eicosanoids such as PGE2, other lipid mediators that in-
clude lipoxins, resolvins, protectins and maresins are also
generated from PUFAs [12].
It is well known that high concentrations of butyrate
prevent NF-kB activation in LPS-stimulated RAW264.7
murine macrophage cells [13]. In addition, other studies
have reported that inhibition of NF-kB induced by bu-
tyrate in IFNγ-stimulated RAW264.7 is implicated in the
butyrate-mediated reduction of TNFα, IL-6 and iNOS
expression [14]. All of these actions, which are mediated
by butyrate, may contribute to the anti-inflammatory ef-
fects of butyrate in inflammatory bowel disease (IBD),
both in experimental models and in humans, where it
has been reported that butyrate suppresses the activation
of HSP70 and NF-kB [15,16]. As dual effect of butyrate,
brain microglial cells were found to be greatly affected.) and relative concentrations of propionic, acetic and
A-intoxicated rats
Mean ± S.D. Percent change P value
0.524 ± 0.064 100.00
0.001
0.674 ± 0.049 128.58
1.228 ± 0.159 100.00
0.001
2.385 ± 0.452 194.12
0.540 ± 0.126 100.00
0.001
0.894 ± 0.086 165.70
0.431 ± 0.069 100.00
0.001
0.291 ± 0.051 67.35
0.433 ± 0.110 100.00
0.1360.363 ± 0.062 83.67
nic acid groups for all parameters.
Table 2 Absolute (nmoles/gm brain tissue) and relative concentrations of PUFAs in the Control and PPA- intoxicated
rats
Parameter Group N Mean ± S.D. Percent change P value
α-Linolenic
Control 8 0.413 ± 0.070 100.00
0.004
Propionic acid 8 0.310 ± 0.019 74.98
Eicosapentaenoic
Control 8 0.428 ± 0.038 100.00
0.006
Propionic acid 8 0.371 ± 0.033 86.70
Docosahexaenoic
Control 8 0.644 ± 0.066 100.00
0.001
Propionic acid 8 0.525 ± 0.047 81.60
Linoleic
Control 8 0.288 ± 0.045 100.00
0.001
Propionic acid 8 0.472 ± 0.042 163.78
γ-Linolenic
Control 8 0.434 ± 0.060 100.00
0.001
Propionic acid 8 0.144 ± 0.012 33.22
Arachidonic
Control 8 0.385 ± 0.040 100.00
0.001
Propionic acid 8 0.306 ± 0.030 79.44
Total omega 3
Control 8 1.072 ± 0.228 100.00
0.001
Propionic acid 8 0.819 ± 0.077 72.20
Total omega 6
Control 8 0.896 ± 0.097 100.00
0.001
Propionic acid 8 0.45 ± 0.033 83.3
omega 6/Omega3
Control 8 0.836 ± 0.056 100.00
0.001
Propionic acid 8 0.502 ± 0.026 100.27
α-Linolenic/Linoleic
Control 8 1.466 ± 0.314 100.00
0.001
Propionic acid 8 0.671 ± 0.066 45.78
α-Linolenic/EPA
Control 8 0.978 ± 0.194 100.00
NS
Propionic acid 8 0.831 ± 0.080 85.00
α-Linolenic/DHA
Control 8 0.648 ± 0.138 100.00
NS
Propionic acid 8 0.625 ± 0.079 96.49
EPA/DHA
Control 8 0.665 ± 0.041 100.00
NS
Propionic acid 8 0.712 ± 0.106 107.15
ARA/Linoleic
Control 8 1.133 ± 0.081 100.00
0.001
Propionic acid 8 0.644 ± 0.065 43.15
ARA/EPA
Control 8 0.901 ± 0.123 100.00
NSPropionic acid 8 0.829 ± 0.124 91.98
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0.2 mM potentiated the LPS-induced secretion of both
IL-6 and nitric oxide [17]. Most interestingly, butyrate
treatment induced a proinflammatory response in trans-
formed N9 microglial cell line and anti-inflammatory re-
sponse in primary, brain-derived microglial cells. In
contrast to the effect of butyrate on pro-inflammatory,
anti-inflammatory cytokines show diverse pattern with
dose-dependent dual effects. IL-10 as an important anti-
inflammatory cytokine is increased by 0.25 mM concen-
tration but significantly decreased by 1 mM of butyrate
[18]. On the other hand, most of pro-inflammatory cyto-
kines are significantly stimulated by high concentration of
PPA [5]. A lower butyrate /propionate ratio was reported
in the present study in the PPA-intoxicated group (Table 1
and Figure 1). This finding could be related and supported
by our previous study in which pro-inflammatory markers(TNFα, INFγ, IL-6, and HSP70) are persistently induced
in rat pups that are orally administered the same neuro-
toxic dose of PPA [6].
It is well known that acetic acid is utilized by hepato-
cytes and transformed into Acetyl-CoA, which can act
as a precursor for lipogenesis and stimulate gluconeo-
genesis [19-21]. Propionic acid is mainly metabolized in
the liver and has been shown to inhibit gluconeogenesis
and increase glycolysis in rat hepatocytes [22]. It has also
been proposed that propionic acid may lower plasma
cholesterol concentrations by inhibiting hepatic choles-
terogenesis [23]. The significantly lower acetic/propionic
ratio reported in the present study (Table 1 and Figure 1)
together with the associated depletion of glucose (a
major energy source for brain cells) and cholesterol
[22,23] can identify PPA-induced neurotoxicity [6,7].
Based on the fact that a deficiency in cholesterol and
Figure 1 Absolute and relative concentrations of SCFAs in control and PPA-intoxicated rats. The mean value for each group is designated
by a line.
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transporters and leads to elevated glutamate, the re-
ported lower acetic/PPA ratio could also be related to
glutamate excitotoxicity, a mechanism that is strongly
involved in the etiology of autism [20].
It is well documented that AA, EPA, and DHA are es-
sential for the normal development and growth of the
brain and of memory [24-27]. AA stimulates glucose up-
take in cerebral cortical astrocytes; thus, it plays a crit-
ical role in the regulation of energy metabolism in the
cerebral cortex [28]. AA and DHA enhance acetylcho-
line (ACh) release, which guarantees long-term synaptic
plasticity, thereby improving learning ability in experi-
mental animals [29]. Several clinical studies have shown
that supplementing infants with AA, EPA, and DHA
significantly improves their cognitive development and
memory [30,31].
Additionally, DHA promotes neuronal survival by fa-
cilitating membrane translocation/activation of Akt,
which is a central player in signal transduction pathways
and thus controls cellular functions such as proliferation
and survival, metabolism, angiogenesis, and exocytosis.
The in vivo reduction of DHA by dietary depletion in-
creases the susceptibility of hippocampal neurons to
apoptosis [32,33].
Based on this information, the significant decrease in
α LA, EPA, DHA, γ-LNA and AA reported in the
present study can be easily related to PPA-neurotoxicity.
Depletion of these PUFAs could indicate impairment of
energy metabolism, loss of synaptic plasticity and in-
creased neuronal susceptibility to apoptosis. These per-
sistent biochemical autistic features were induced in rat
pups that were orally administered the same neurotoxic
dose of PPA [6]. The observed variation in the absolute
and relative concentrations of FFA could be also related
to the pro-inflammatory effects of PPA. While AA isconsidered a pro-inflammatory lipid, γ-LNA, EPA and
DHA have been viewed as anti-inflammatory molecules
due to their capacity to reduce the production of pro-
inflammatory cytokines via the NF-κB signaling pathway
[34,35]. Moreover, EPA is itself a substrate for cyclooxy-
genase and lipoxygenase, giving rise to mediators that
often have biological effects opposite to those of AA.
Linoleic acid (LA) is an essential dietary fatty acid that
is crucial to neonatal development. It is necessary for
the growth and development of the brain and other body
tissues that are dependent on AA, the central n-6 eicosa-
noid precursor synthesized from LA via elongation-
desaturation [36]. Desaturase and elongase enzymes
insert double bonds and elongate carbon chains to cre-
ate PUFA from essential fatty acid (EFA) precursors [37].
It appears that the same enzymes catalyze the conver-
sion of both omega-6 and omega-3 fatty acid precursors
into PUFAs. Lower desaturase activity, which is esti-
mated by the ratio of AA to LA, might also be a neuro-
toxic effect of PPA. A 56.85% reduction in AA/LA could
confirm the toxic effect of PPA on the brains of treated
rat pups. A link between fatty acid desaturation genes
and attention-deficits was previously suggested [38]. The
non-significant change observed in αLA/EPA and αLA/
DHA could be attributed to differences in Km values
and affinity between the fatty acid desaturase enzyme
and the substrates LA, ALA, EPA and DHA. This sug-
gestion could be supported by the remarkable lower
αLA/LA ratio, which are precursors for ω3 and ω 6
respectively.
Furthermore, PUFAs could be related to the neuro-
chemical activity of the brain. These acids could control
the expression, properties, and action of dopamine, sero-
tonin (5-HT), and Ach [39,40], especially during the
perinatal period. During this period the growth and de-
velopment of brain is at a maximum and ACh, in turn,
Figure 2 (a-e) Absolute and relative concentrations of PUFAs in control and PPA-intoxicated groups. The mean value for each group is
designated by a line.
Table 3 ROC analysis represented as area under the curve (AUC), specificity and sensitivity for the measured SCFA in
the PPA-intoxicated groups
Area under the curve Best cutoff value Sensitivity % Specificity %
Acetic 1.000 0.603 100.0% 100.0%
Propionic 1.000 1.560 100.0% 100.0%
Butyric 1.000 0.740 100.0% 100.0%
Acetic/propionic 0.969 0.336 87.5% 100.0%
Butyric/propionic 0.625 0.375 62.5% 75.0%
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Table 4 ROC analysis represented as area under the curve (AUC), specificity and sensitivity for the measured PUFA in
the PPA-intoxicated groups
Area under the curve Best cutoff value Sensitivity % Specificity %
α-Linolenic 0.875 0.337 100.0% 87.5%
Eicosapentaenoic 0.883 0.405 87.5% 75.0%
Docosahexaenoic 0.938 0.595 100.0% 87.5%
Linoleic 1.000 0.386 100.0% 100.0%
γ-Linolenic 1.000 0.241 100.0% 100.0%
Arachidonic 0.938 0.338 87.5% 87.5%
Oleic 0.922 0.673 100.0% 87.5%
Total omega 3 0.609 1.690 75.0% 62.5%
Total omega 6 1.000 0.565 100.0% 100.0%
Omega6/omega 3 1.000 0.342 100.0% 100.0%
α-Linolenic/Linoleic 0.984 1.080 100.0% 87.5%
α-Linolenic/EPA 0.828 0.865 87.5% 87.5%
α-Linolenic/DHA 0.656 0.689 87.5% 62.5%
EPA/DHA 0.641 0.728 50.0% 100.0%
γ-Linolenic/ARA 1.000 0.817 100.0% 100.0%
ARA/EPA 0.625 0.896 87.5% 50.0%
Table 5 Pearson correlations between the neurotoxin PPA
and different measured absolute and relative concentrations
of SCFAs and PUFAs
Parameters R (Pearson Correlations) Sig.
Propionic ~ Acetic 0.817** 0.001 Pa
Propionic ~ Butyric 0.845** 0.001 Pa
Propionic ~ Acetic/propionic −0.892** 0.001 Nb
Propionic ~ Butyric/propionic −0.495 0.051 Nb
Propionic ~ α-Linolenic −0.604* 0.013 Nb
Propionic ~ Stearidonic 0.888** 0.001 Pa
Propionic ~ Eicosapentaenoic −0.397 0.128 Nb
Propionic ~ Docosahexaenoic −0.561* 0.024 Nb
Propionic ~ Linoleic 0.865** 0.001 Pa
Propionic ~ γ-Linolenic −0.826** 0.001 Nb
Propionic ~ Arachidonic −0.735** 0.001 Nb
Propionic ~ Oleic −0.530* 0.035 Nb
Propionic ~ Total omega 3 −0.070 0.797 Nb
Propionic ~ Total omega 6 −0.825** 0.001 Nb
Propionic ~ Omega6/omega 3 −0.867** 0.001 Nb
Propionic ~ α-Linolenic/Linoleic −0.786** 0.001 Nb
Propionic ~ α-Linolenic/EPA −0.486 0.056 Nb
Propionic ~ α-Linolenic/DHA −0.022 0.935 Nb
Propionic ~ EPA/DHA 0.317 0.232 Pa
Propionic ~ γ-Linolenic/AA −0.812** 0.001 Nb
Propionic ~ AA/EPA −0.468 0.067 Nb
aPositive Correlation.
bNegative Correlation.
*Correlation is significant at the 0.05 level (2-tailed).
**Correlation is significant at the 0.01 level (2-tailed).
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and AA modulate neural function, including neurotrans-
mission, membrane fluidity, ion channel, enzyme regula-
tion and gene expression and prevent inflammation.
They could therefore be of significant benefit in the pre-
vention and management of autism.
Fatty acids may exert structural effects on membranes,
either as free entities (i.e. FFA) or as part of other mole-
cules such as phospholipids and triacylglycerides. Omega-
3 fatty acids have a curved shape, allowing gaps between
molecules when they are incorporated into cell mem-
branes. These gaps increase the fluidity of the membrane,
enabling cell-to-cell communication with the aid of ion
channels [42]. In contrast, omega-6 fatty acids are straigh-
ter and narrower and therefore reduce the fluidity of the
membrane due to a remarkable decrease in the gaps be-
tween cells. Consequently, it is important that the ratio of
the PUFA types remains balanced to preserve optimal
functioning of the cell membrane [43].
The lower α-Linolenic acid and DHA reported in the
present study (Table 2 and Figure 2) can also be related
to impaired serotonin transmission, which was previ-
ously reported in rat pups either orally administered (the
same toxic dose) or intraventricularly infused with PPA
[6,7]. α-Linolenic and DHA deficient rats exhibited sig-
nificantly lower prefrontal cortex 5-HT content, greater
5-hydroxyindoleacetic acid 5-HIAA content, a signifi-
cantly greater 5-HIAA/5-HT ratio, and a decrease in
midbrain tryptophan hydroxylase-2 expression, which is
a rate limiting enzyme in the 5-HT biosynthesis path-
way. This finding suggests that a relationship exists
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sion and omega-3 fatty acid deficiency [44].
In addition, ω -3 fatty acids may modulate biochemical
and physiological responses that are implicated in neuro-
development via their effects on nuclear transcription
factors, especially those involved in immunologic dys-
function. In vitro neuronal cell studies have revealed
DHA to be a potent ligand for peroxisome proliferator-
activated receptor γ (PPAR γ), which results in a sup-
pression of proinflammatory genes that encode various
interleukins and tumor necrosis factor (TNF)-α [45].
The significantly lower ω 3, ω6 and ω 6/ω 3 ratios re-
ported in the present study (Table 2 and Figure 2) are
consistent with the previous work of Thomas et al. [46],
in which PPA infusion in rats decreased the total levels
of monounsaturates, ω 6 fatty acids, and phosphatidyl-
ethanolamine plasmalogens and decreased the ω 6/ω 3
ratio, providing evidence of a relationship between
changes in brain lipid profiles and autism-like behaviors
in a rodent model.
Changes in behavior and brain integrity in adult rodents
following transient selective serotonin (5-HT) reuptake in-
hibitors (SSRIs) such as fluoxetine may be related to dis-
turbed AA neurotransmission and metabolism because
AA is released from synaptic membrane phospholipids
during neurotransmission involving 5-HT2A/2C receptors
[47-50]. As a second messenger, AA can modify multiple
aspects of brain function and structure. It is a precursor of
a large number of bioactive eicosanoid products within
the brain’s AA metabolic cascade [51,52].
Anti-inflammatory ω-3 derived EPA and DHA block so-
dium (Na+) channels in a dose and time dependent man-
ner in neonatal rat ventricular myocytes [53,54]. This in
turn limits the activity of the Na+/Ca+2 exchanger, which
regulates intracellular Ca+2 influx. In vivo cell culture
studies demonstrate that both EPA and DHA increase
cellular inactivation in the Cornu Ammonis area (CA1)
region of the hippocampus, thus reducing Ca+2 influx-
associated cellular activity [55]. Thus, PUFAs are likely to
reduce intracellular Ca+2 influx-associated excitotoxicity.
In the present study, the impaired relative and abso-
lute fatty acid levels could be related to mitochondrial
dysfunction as an etiological mechanism in autism. PPA
is thought to affect mitochondrial fatty acid metabolism
by binding to propionyl Coenzyme A and by sequestering
carnitine [56,57]. This in turn induces potential metabolic
disturbance by affecting mitochondrial β-oxidation and
bioenergetics. On the other hand, impaired fatty acid oxi-
dation activates uncoupling protein-2 (UCP-2), which re-
sults in heat generation that does not contribute to ATP
production [58,59].
The receiver operating characteristic (ROC) analysis
(Tables 3 and 4) showed that most of the measured rela-
tive values for fatty acids can be used as biomarkers forPPA neurotoxicity, recording satisfactory specificity, sen-
sitivity and AUC. While elevated propionic acid is sig-
nificantly correlated with levels of acetic, butyric,
stearidonic and linoleic acid, it is inversely associated
with the rest of the absolute and relative values of
PUFAs (Table 5). Omega 6 fatty acids, represented by γ-
LA and AA, were more significantly related to PPA-
neurotoxicity than ω-3 fatty acids (ALA, EPA, and
DHA). γ-LA, AA, DHA and EPA all play key roles in
brain function, especially via the synthesis of eicosanoids
that have anti-inflammatory, anti-thrombotic, and vaso-
dilatory properties [60]. Therefore, the inverse associ-
ation between PPA level and the levels of these acids
confirm that the neurotoxic dose of this short chain fatty
acid used in this study (250 mg/kg body weight/day for
three days) was effective in inducing an alteration in the
brain fatty acid profile. These results provide evidence
for a relationship between changes in brain lipid profiles
and the occurrence of ASD-like biochemical alterations
in a rodent autism model [6]. This can be easily sup-
ported by the positive associations between brain malon-
dialdehyde (MD) and short chain fatty acids (PA and
acetic acid), and the negative correlations between poly-
unsaturated fatty acids and MD as marker of increased
oxidative stress, a status recently related to the aetiology
and clinical presentation of autism [6,61]. Another sup-
port can be easily found in our recent work in which im-
paired plasma phospholipids and relative amounts of
essential polyunsaturated fatty acids were recorded as
predictive biomarkers in Saudi patients with autism [62].
Based on this, we propose that altered absolute and rela-
tive amounts of fatty acids may contribute to ASD and
can be used as biomarkers for early detection of neuro-
toxicity related to this disorder.Competing interests
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